Peptides
Retatrutide
In plain language
A newer, more powerful weight-loss peptide, similar in concept to semaglutide/tirzepatide but not yet on the market.
Hard safety warning
Not a real, regulated product — do not buy this online.
Is it an approved medication?
No — not an approved medication
NO - still in Phase 3 clinical trials, not yet approved anywhere
How strong is the evidence?
Promising early human data, but the full picture is not in yet
The main thing to know
There is currently no legitimate way to buy this - anything sold online under this name is not a real, regulated product.
Mechanism
Triple agonist targeting GIP, GLP-1, and glucagon receptors; combines incretin and energy-expenditure pathways.
Potential benefits
- Weight loss (largest magnitude reported among incretin therapies in Phase 2 data)
- Glycemic control in type 2 diabetes
Regulatory status
Not yet approved - Phase 3 trials ongoing as of 2026 (verify current status)